Skip to content
OpenCapital
Get started

Allogene Therapeutics ALLO Operating Lease Weighted Average Discount Rate Percent

Operating Lease Weighted Average Discount Rate Percent at other companies

Precigen logo
PrecigenPGEN
——
Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
——

Other financials

Income statement

See full
Revenue-—
Operating income-$46.1M+29.3%
Net income-$42.6M+28.7%
EPS (diluted)-$0.18+35.7%

Balance sheet

See full
Cash & equivalents$40.6M-23.0%
Total debt$81.1M-8.9%
Total equity$278.9M-27.6%
Total assets$396.0M-22.1%

Cash flow

See full
Operating cash flow-$12.9M+75.6%
CapEx$9.0K-90.9%
Free cash flow-$12.9M+75.6%

Valuation

See full
Market cap$711.02M+164%
Enterprise value$751.47M+146%

Profitability

See full
Operating margin-1,241,813.6%-2,018,140pp
Net margin-1,170,863.6%-2,007,890pp
FCF margin-913,609.1%-1,474,890pp

Returns & leverage

See full
Return on equity-52.3%-5.7pp
Debt / equity0.3×+0.1×
Current ratio9.6×-0.1×

Where this comes from

Reported directly by Allogene Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent.

The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Allogene Therapeutics's operating lease weighted average discount rate percent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Allogene Therapeutics's operating lease weighted average discount rate percent?
Allogene Therapeutics (ALLO) reported operating lease weighted average discount rate percent of $0.07 in Q1 2026.
How has Allogene Therapeutics's operating lease weighted average discount rate percent changed year-over-year?
Allogene Therapeutics's operating lease weighted average discount rate percent increased by 3.8% year-over-year, from $0.06 to $0.07.